Soricimed Phase 1 Trials to Proceed
Sackville, N.B.-based biotech Soricimed Biopharma Inc. said this week that the Food and Drug Administration in the U.S. and Health Canada have given it the green light to proceed with Phase 1 trials for its main drug candidate, an anti-cancer agent called SOR-C13.
“Acceptance by the FDA and Health Canada of this application, along with the advancement of SOR-C13 to clinical testing, are two major milestones for Soricimed and key steps along the path to the drug's development and commercialization,” Jack Stewart, Chairman and Chief Scientific Officer of the company, said in a press